It is now easier for GPs to prescribe hepatitis C treatment

Changes to the Pharmaceutical Benefits Schedule in 2016 have made it possible for GPs to prescribe treatment to patients with hepatitis C. With nearly 90% of these patients yet to receive their treatment, your clinic can really make a difference! Testing and treating patients is simple: new treatments result in virtually no side effects and […]


Hepatitis ACT has learned of recent concerns about a small number of cases nationally of hepatitis A apparently linked to a batch of frozen berries. At the time of writing there has been three cases reported (one in each of Victoria, Queensland and South Australia). Entyce Food Ingredients has recalled their 300g ‘Creative Gourmet Mix […]

The Importance of testing after completing hepatitis C treatment

This notice is prompted by conversations with community hepatitis organisations, specialists, doctors and health consumers. This advice comes with the strong endorsement of Associate Professor Simone Strasser, Senior Staff Specialist at the AW Morrow Gastroenterology and Liver Centre at the Royal Prince Alfred Hospital in Sydney. It is absolutely essential for anyone and everyone undergoing […]

Australasian Viral Hepatitis Elimination Conference 2017

The inaugural Australasian Viral Hepatitis Elimination Conference 2017, taking place at the Pullman Cairns International, Queensland, 10–11 August 2017, aims to gather those working in the field of Viral Hepatitis – as well as policy makers, researchers, primary health care providers and other individuals committed towards virtual hepatitis elimination. The program will present the latest […]

Hepatitis B Vaccine Shortage

Hepatitis ACT understands from pharmaceutical company GlaxoSmithKline (GSK) that there is a national shortage of the adult dose of the hepatitis B vaccine, and as a result they say “GSK prioritises hepatitis B vaccine availability for those most at risk of infection and confirms uninterrupted supply of Engerix-B to all Australian State, Territory and Federal […]

Safety advisory – risk of hepatitis B virus reactivation

19 December 2016 Consumers and Healthcare Professionals are advised that direct-acting antiviral (DAA) medicines for the treatment of chronic hepatitis C virus (HCV) infection have been associated with reactivation of hepatitis B virus (HBV) in patients with a current or previous HBV infection. A recent TGA review of the available data, including data from international […]